Dr.François-Xavier MahonProfesseur d’Université Praticien hospitalier
Hématologie CHU Bordeaux Université Bordeaux, France |
 |
Discontinuation of imatinib may be possible in chronic myelogenous leukemia
March 3, 2011,Cancer Journal for Clinicians
Some With Once-Deadly Leukemia Can Take a Break From Gleevec
October 2010, Medline Plus
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
October 2010, The Lancet Oncology
Some leukemia patients may be able to safely stop treatment
October 2010, PhysOrg.com
Leucémie myéloïde chronique
Juillet 2008, John Libbey Eurotext
